Treatment library
Loading treatment roster
Preparing current medications, procedures, devices, and historical context.
Treatment library
Preparing current medications, procedures, devices, and historical context.
A branded naltrexone / bupropion combination approved for chronic weight management. It remains part of the non-GLP-1 obesity toolkit, especially for patients considering oral options.
FDA-approved for chronic weight management in eligible adults alongside diet and physical activity.
Central appetite and reward-pathway modulation
Insurance treatment varies widely and obesity-drug exclusions still limit access in many plans.
Central appetite and reward-pathway modulation
A branded naltrexone / bupropion combination approved for chronic weight management. It remains part of the non-GLP-1 obesity toolkit, especially for patients considering oral options.
medication
current
2014
Contrave
naltrexone / bupropion extended release
Currax Pharmaceuticals
No identical generic extended-release combination equivalent.
naltrexone, bupropion
Branded oral therapy with lower sticker shock than the newest injectables but still variable out-of-pocket cost.
Insurance treatment varies widely and obesity-drug exclusions still limit access in many plans.
FDA-approved for adults with BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity, when used alongside diet and physical activity. May appeal when an oral option is preferred and seizure risk, psychiatric history, or opioid use do not make it a poor fit.
Adults with BMI of 30 or higher (obesity), or BMI of 27 or higher (overweight) with at least one weight-related comorbidity.
The naltrexone component may dampen food cravings through reward-pathway effects, which makes Contrave different in kind from the GLP-1 drugs. Weight loss in trials averaged roughly 5-6%, well below Wegovy (roughly 15%) or Zepbound (roughly 20%). It is oral and avoids injection. The bupropion component carries a boxed warning on suicidal thoughts and behavior, and the drug is ruled out for patients with seizure disorders, eating disorders, or concurrent opioid use.
Contrave is still prescribed as an oral alternative in obesity care, especially when patients or clinicians want to avoid injectables.
Carries boxed warning language related to suicidal thoughts and behavior from the bupropion component and is not appropriate for some seizure, eating-disorder, or opioid-use contexts.
nausea, constipation, headache, dry mouth, insomnia
Central appetite and reward-pathway modulation
Oral tablets titrated over several weeks to twice-daily maintenance dosing.
Oral extended-release tablet.
These are the official or reference sources used to anchor this treatment profile.
Treatment availability, dosing, cash pricing, and insurance coverage change often. Verify current details with your clinician, pharmacist, surgeon, device program, and insurer before starting, switching, or paying for treatment.